EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY 4.0

Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide

Jianghe Yan, Guangting Zeng

JACC: Advances · 2026-12 · 5 (12) · 103402

DOI: 10.1016/j.jacadv.2026.103402 ↗

Kurz gefasst

Leserbrief in der Zeitschrift JACC: Advances, 2026-12. Verfasst von Jianghe Yan und 1 weiteren Autor:innen. Beteiligte Einrichtung: The First People's Hospital of Chenzhou, Xiangnan University, Chenzhou, China. Die Arbeit nennt 1 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Methodological ConcernsWe read with great interest the target trial emulation study by Azzam et al 1 comparing cardiovascular and cerebrovascular outcomes between semaglutide and tirzepatide.However, several methodological aspects of this study merit further clarification.

Autor:innen und Institutionen

  • The First People's Hospital of Chenzhou, Xiangnan University, Chenzhou, China.
  • The First People's Hospital of Chenzhou, Xiangnan University, Chenzhou, China. Electronic address: guangtingzeng2025@163.com.

Zitieren

APA

Yan, J., & Zeng, G. (2026). Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide. JACC: Advances, 5(12), 103402. https://doi.org/10.1016/j.jacadv.2026.103402

Vancouver

Yan J, Zeng G. Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide. JACC: Advances. 2026;5(12):103402. doi:10.1016/j.jacadv.2026.103402

BibTeX
@article{Yan2026,
  author = {Yan, Jianghe and Zeng, Guangting},
  title = {Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide},
  journal = {JACC: Advances},
  year = {2026},
  volume = {5},
  number = {12},
  pages = {103402},
  doi = {10.1016/j.jacadv.2026.103402}
}
Kostenlos starten →